Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Daraxonrasib Sparks Hope and Demand Surge for Deadly Pancreatic Cancer Treatment

Published

on

Weight Watchers App Down for Hundreds as Users Report Sign-In

NEW YORK — An experimental drug showing dramatic potential to extend survival for patients with one of the deadliest forms of cancer is generating intense demand at specialized clinics across the country as patients and oncologists await full regulatory approval.

Daraxonrasib, which targets the KRAS gene mutation present in roughly 90 percent of pancreatic cancer cases, received fast-track early access authorization from the Food and Drug Administration on April 30. The medication has already demonstrated in clinical trials the ability to nearly double median survival times for patients with advanced disease, prompting a rush of inquiries from desperate families and oncologists seeking options for those with limited time left.

Pancreatic cancer remains one of the most lethal malignancies, with a five-year survival rate below 13 percent and limited treatment options once it spreads. Traditional chemotherapy regimens typically extend life by only a few months. Daraxonrasib’s early results have therefore generated unprecedented excitement in the oncology community, with some physicians describing it as a potential game-changer for a disease long considered nearly untreatable.

Breakthrough Targets Root Cause

The drug works by specifically inhibiting the mutated KRAS protein that drives uncontrolled cell growth in most pancreatic tumors. In Phase 2 trials involving patients with metastatic disease, those receiving Daraxonrasib alongside standard chemotherapy saw median overall survival approach 18 months — nearly double the typical 9 to 11 months seen with chemotherapy alone. Some participants experienced tumor shrinkage significant enough to become eligible for surgery, an outcome rarely seen in advanced pancreatic cancer.

Advertisement

Dr. Elena Ramirez, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center, called the results “remarkable” but cautioned that larger Phase 3 data is still needed. “For the first time in decades, we’re seeing a targeted therapy that directly attacks the primary driver mutation in this terrible disease,” she said. “Patients are understandably eager, but we must balance hope with rigorous science.”

Clinics Overwhelmed by Demand

Since the FDA‘s early access approval, specialized cancer centers have reported a sharp increase in requests. Some clinics say they are fielding dozens of calls daily from patients seeking enrollment in expanded access programs. Demand has been particularly high in states with strong pancreatic cancer advocacy networks, including California, Texas and New York.

“We’ve never seen anything like this volume,” said Dr. Michael Chen, medical director of a pancreatic cancer program in Houston. “Patients who were told they had months left are now asking about this drug by name. We’re doing our best to evaluate them quickly and fairly, but supply is limited while full approval is pending.”

The manufacturer has not yet disclosed exact production capacity or pricing for the early access program. Industry analysts estimate monthly treatment costs could exceed $20,000, raising concerns about equitable access even before widespread availability. Patient advocacy groups are already calling on insurers to cover the therapy under compassionate use provisions.

Advertisement

Patient Stories Fuel Optimism

Early participants in the expanded access program have shared cautiously hopeful stories. One 58-year-old patient from Florida, who asked to remain anonymous, said the drug stabilized his tumors after standard treatments failed. “For the first time in a year, I feel like I have time again,” he told local media. “I’m not cured, but I’m still here.”

Such testimonials have spread rapidly on social media, creating both inspiration and pressure on the healthcare system. Pancreatic cancer advocacy organizations report record website traffic and helpline calls since the FDA announcement.

Scientific and Regulatory Path Ahead

Daraxonrasib is currently in late-stage clinical trials, with full FDA approval potentially arriving as early as late 2027 if data remains strong. The drug’s developer has prioritized pancreatic cancer but is also studying its effectiveness against other KRAS-mutated tumors, including certain lung and colorectal cancers.

Oncologists stress that while promising, the drug is not a miracle cure. Side effects include fatigue, gastrointestinal issues and skin reactions, similar to other targeted therapies. Long-term survival benefits and potential resistance mechanisms are still being evaluated.

Advertisement

The National Cancer Institute has highlighted Daraxonrasib as one of several KRAS inhibitors showing real progress after decades of failed attempts to drug this notoriously difficult target. Success against KRAS has long been considered the “holy grail” of precision oncology.

Broader Implications for Cancer Care

If fully approved, Daraxonrasib could reshape treatment paradigms for pancreatic cancer and influence research into other hard-to-treat malignancies. It represents a shift toward mutation-specific therapies rather than broad chemotherapy approaches that have dominated care for decades.

However, experts warn that early access programs, while lifesaving for some, can create ethical challenges around equity. Wealthier patients and those near major cancer centers are more likely to secure spots, potentially widening survival gaps.

Advocacy groups are pushing for expanded compassionate use and accelerated approval pathways to ensure broader availability. They also emphasize the importance of continued research funding for pancreatic cancer, which receives significantly less attention than more common malignancies despite its high mortality rate.

Advertisement

Hope Tempered by Reality

For the thousands of families facing pancreatic cancer diagnoses each year, Daraxonrasib represents a rare beacon of hope in a disease that has long offered little. While the drug is not yet a cure, its ability to meaningfully extend life has already changed conversations in oncology offices nationwide.

As clinics work to meet surging demand and researchers push forward with larger trials, the coming months will be critical in determining whether this experimental therapy fulfills its early promise. For patients and loved ones currently battling the disease, even the possibility of additional time is profoundly meaningful.

The medical community remains cautiously optimistic. Daraxonrasib has ignited excitement not seen in pancreatic cancer for years, but sustained benefits and broad accessibility will ultimately determine its place in treatment history. For now, patients continue seeking enrollment while researchers race to gather the definitive data needed for full approval.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Honda posts first-ever annual loss over electric vehicle strategy

Published

on

Honda posts first-ever annual loss over electric vehicle strategy

Honda Motor posted its first-ever annual loss this week since it was first listed on the stock market in 1957.

The Japanese car company’s bet on electric vehicle sales left it with $9 billion in restructuring costs due to low demand and President Donald Trump’s “Made in America” policies.

Advertisement

“EV demand has declined considerably, due to the rollback of environmental regulations in the U.S. and other factors,” Honda said in a statement.

CEO Toshihiro Mibe said on Thursday that the company, which suffered a $2.7 billion loss, would also abandon its target to make electric vehicle sales 20% of profits by 2030.

TRUMP ESCALATES BATTLE WITH NEWSOM, SHUTTING DOWN GOVERNOR’S LEFT-WING RULES ROCKING CAR INDUSTRY

Honda CEO speaking

Honda’s Chief Executive Toshihiro Mibe speaks at a press conference in Tokyo Thursday, May 14, 2026. (Yuta Omori/Kyodo News via AP / AP Newsroom)

The company had also previously set a goal to fully move to electric or fuel-cell vehicles by 2024.

Advertisement

Losses related to its electric vehicle operations are expected to reach $16 billion, the company said.

The Trump administration has moved away from electric vehicle incentive programs, including blocking California’s stringent electric vehicle mandates and removing former President Joe Biden’s EV tax credit.

MASSIVE HONDA RECALLIMPACTS 440K VEHICLES OVER AIRBAGS POTENTIALLY DEPLOYING ‘UNEXPECTEDLY’

Honda, however, stemmed the bleeding through an increase in motorcycle sales – 20 million more than last year, which translated to a half a percent increase or $138 billion for the fiscal year through March.

Advertisement
Honda Dealership

The logo of Honda seen at a dealership store. (Photo by Igor Golovniov/SOPA Images/LightRocket via Getty Images / Getty Images)

Honda, which makes the Accord sedan and Super Cub motorcycles, sold 3.4 million vehicles around the world in the fiscal year through March, down from 3.7 million the previous year.

The company is the main motorcycle seller in some markets, including India.

Despite the loss, Honda is still forecasting a $1.7 billion profit for the fiscal year through March 2027.

Honda electric vehicle

Visitors look at a HONDA E:N2 electric car on display at the 47th Bangkok International Motor Show 2026 in March.  (Anusak Laowilas/NurPhoto via Getty Images / Getty Images)

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Advertisement

“We will continue our research to develop future technologies including electric vehicle batteries,” Mibe said. “We will get back on a growth track,” adding that the company will continue a goal of carbon neutrality while acknowledging the need to work on hybrids and regular gasoline-engine models as well.

Reuters and the Associated Press contributed to this report.

Continue Reading

Business

Natera co-founder Sheena Jonathan sells $959,450 in company stock

Published

on


Natera co-founder Sheena Jonathan sells $959,450 in company stock

Continue Reading

Business

MJ GOAT Debate Far From Over Despite Lakers Elimination

Published

on

Bronny James

LOS ANGELES — The Los Angeles Lakers’ second-round playoff exit at the hands of the Oklahoma City Thunder has reignited one of sports’ most enduring arguments: the Michael Jordan versus LeBron James GOAT debate. At 41 years old, James once again delivered elite production in the postseason, yet the Lakers’ early departure has prompted fresh claims from Jordan loyalists that the conversation is finally settled in favor of the six-time champion. Most analysts and players, however, insist the discussion remains very much alive.

Michael Jordan and Scottie Pippen having a little chat in the middle of a game against Charlotte Hornets in May 1998.
Michael Jordan and Scottie Pippen having a little chat in the middle of a game against Charlotte Hornets in May 1998.

The Lakers fell to the top-seeded Thunder in a competitive but ultimately lopsided series, with James posting strong individual numbers even as his supporting cast struggled against Oklahoma City’s depth and defensive intensity. James’ continued excellence at an age when most players have long retired has only deepened the divide among fans and commentators. Jordan advocates point to his perfect 6-0 NBA Finals record and unmatched killer instinct, while LeBron supporters highlight longevity, versatility, and statistical dominance across four different franchises.

Perkins and Others Weigh In

ESPN analyst Kendrick Perkins stirred the pot earlier this season by declaring Victor Wembanyama the most dominant player currently, but the broader GOAT conversation always circles back to James and Jordan. James himself has repeatedly downplayed the debate, calling it “barbershop talk” and noting that he and Jordan played fundamentally different styles. In a recent wide-ranging interview, James emphasized his role as a point-forward who prioritizes playmaking over Jordan’s scoring-first mentality.

Jordan, who has largely stayed silent on the matter in recent years, maintains a legendary aura built on six titles, six Finals MVPs and an unmatched winning pedigree. His supporters argue that no amount of regular-season longevity or statistical accumulation can overcome Jordan’s flawless championship record and cultural impact during his prime. LeBron’s four rings and 10 Finals appearances, achieved with three different teams, demonstrate adaptability but also fuel arguments about team-hopping versus Jordan’s loyalty to the Chicago Bulls.

Longevity vs. Peak Dominance

At the heart of the debate lies a philosophical difference in how greatness is measured. Jordan’s peak from 1991 to 1998 remains the gold standard for many: undefeated in the Finals, relentless defensively, and clutch in the biggest moments. James counters with an unprecedented 21 All-NBA selections, the all-time scoring record, and the ability to elevate mediocre rosters to contention well into his 40s. His 2026 playoff performance, leading the Lakers in scoring and assists despite the loss, only reinforced that narrative for his backers.

Advertisement

Advanced metrics tell a nuanced story. James ranks among the all-time leaders in playoff wins, series-clinching victories and versatility stats. Jordan’s efficiency in high-stakes moments and defensive impact during his championship runs still set benchmarks. Younger analysts increasingly favor LeBron for his statistical accumulation and influence on modern basketball, while older observers and many former players side with Jordan’s aura and perfection.

Social media exploded after the Lakers’ elimination, with hashtags like #MJGOAT and #LeBronGOAT trending simultaneously. Some declared the debate “over” citing the sweep, while others pointed to James’ individual brilliance at 41 as further evidence of his unparalleled career. The discourse revealed deep generational divides, with millennials and Gen Z leaning toward LeBron’s longevity argument.

LeBron’s Own Perspective

James has consistently refused to engage deeply in the comparison. “Our games are totally different,” he said earlier this season. “I’ve always looked for the pass first.” He has expressed admiration for Jordan, wearing No. 23 in homage and hoping to make his idol proud. In quieter moments, James has said the only opinion that matters is his own self-assessment at the end of his career.

Jordan, for his part, has avoided direct commentary in recent years, preferring to let his résumé speak for itself. The two icons share mutual respect, with James often citing Jordan as a primary influence and Jordan acknowledging LeBron’s unique place in the game.

Advertisement

What the Future Holds

With James potentially playing alongside his son Bronny and showing no signs of sharp decline, the debate could continue for another season or two. Another deep playoff run or a fifth championship would significantly bolster LeBron’s case. Conversely, Jordan’s untouchable Finals record remains a powerful anchor for his supporters. Most neutral observers now view the conversation as unresolvable, more a matter of personal preference than objective fact.

The 2026 postseason exit changes little in the grand scheme. James once again proved he can perform at an All-NBA level deep into his career, a feat unmatched in league history. Jordan’s six titles in eight years remain legendary. Both players redefined excellence in their eras, and both will be remembered as all-time greats regardless of where the endless online arguments land.

As the NBA moves forward with a new generation of stars, the Jordan-James debate endures as a celebration of basketball excellence rather than a zero-sum contest. Their combined impact has elevated the league’s global popularity and inspired countless players. Whether one prefers Jordan’s perfection or LeBron’s longevity, the conversation itself enriches the sport and ensures both legends remain central to its story.

The GOAT debate is far from over — and that’s exactly how basketball fans seem to prefer it. As long as highlights are watched, stats are debated and new generations discover these icons, the conversation will thrive. LeBron James’ latest playoff run, though ending in elimination, only added more chapters to one of sports’ greatest ongoing narratives.

Advertisement
Continue Reading

Business

Fiserv, Inc. (FISV) Analyst/Investor Day Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Company Participants

Walter Pritchard – Senior VP & Head of Investor Relations
Michael Lyons – CEO & Director
Takis Georgakopoulos – Co-President and COO of Technology & Merchant Solutions
Dhivya Suryadevara – Co-President and Head of Financial Solutions, Sales & Operations
Paul Todd – Chief Financial Officer

Conference Call Participants

Advertisement

James Friedman – Susquehanna Financial Group, LLLP, Research Division
Andrew Schmidt – KeyBanc Capital Markets Inc., Research Division
Kartik Mehta – Northcoast Research Partners, LLC
Vasundhara Govil – Keefe, Bruyette, & Woods, Inc., Research Division
Dan Dolev – Mizuho Securities USA LLC, Research Division
Timothy Chiodo – UBS Investment Bank, Research Division
Dominick Gabriele – Loop Capital Markets LLC, Research Division
Bryan Bergin – TD Cowen, Research Division
Harshita Rawat – Bernstein Institutional Services LLC, Research Division
Darrin Peller – Wolfe Research, LLC
Jason Kupferberg – Wells Fargo Securities, LLC, Research Division
Bryan Keane – Citigroup Inc., Research Division
Tien-Tsin Huang – JPMorgan Chase & Co, Research Division
David Koning – Robert W. Baird & Co. Incorporated, Research Division
William Nance – Goldman Sachs Group, Inc., Research Division

Presentation

Operator

Advertisement

Please welcome Head of Investor Relations, Walter Pritchard.

Walter Pritchard
Senior VP & Head of Investor Relations

Thank you, everybody, for coming, both here in New York and on the webcast. Before we kick off, I wanted to review the agenda and provide some information on logistics. We’ll start today with Mike reviewing our strategy and our plans to execute the strategy. Then Takis will follow with a deep dive into the merchant business, and at about 10:15, we’ll take a short break. We have coffee and some light snacks out in the lobby area. At this time, those on the webcast, we’ll hear the music.

Advertisement

We will return at 10:30 with Dhivya, taking us through the Financial Solutions business, and then we’ll have Takis join Dhivya

Advertisement
Continue Reading

Business

Trio-Tech director Jason Adelman sells $123,570 in common stock

Published

on


Trio-Tech director Jason Adelman sells $123,570 in common stock

Continue Reading

Business

Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock

Published

on


Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock

Continue Reading

Business

Taiyo Yuden Co., Ltd. 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:TYOYY) 2026-05-15

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

Koito Manufacturing Co., Ltd. 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:KOTMY) 2026-05-15

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

Thai PM Anutin confronts legal battle over 400B baht emergency loan during crisis

Published

on

Thai PM Anutin confronts legal battle over 400B baht emergency loan during crisis

Thailand’s opposition is challenging Prime Minister Anutin’s plan to borrow 400 billion baht to mitigate the Middle East conflict’s impact and cost of living crisis. They argue current economic conditions don’t justify such borrowing, questioning the funding for energy transition.


Key Points

  • Thailand’s opposition is challenging Prime Minister Anutin’s plan to borrow 400 billion baht (S$15.7 billion) via an emergency decree.
  • The funds are for cash handouts, farmer assistance, and a renewable energy transition, but opposition parties argue the country’s growth and fiscal space don’t justify the debt.
  • They are seeking a Constitutional Court ruling to suspend the decree, citing concerns about fiscal discipline and the necessity of debt-financing the energy transition.

Opposition Challenges Massive Borrowing Plan

Thailand’s main opposition parties, the People’s Party and the Democrat Party, are actively challenging Prime Minister Anutin Charnvirakul’s plan to borrow 400 billion baht. This substantial sum is intended to mitigate the economic repercussions of the Middle East conflict and alleviate the cost-of-living crisis. The government has authorized this borrowing through an emergency decree, aiming to fund cash handouts to approximately 30 million citizens and provide support to farmers, fisherfolk, and small businesses impacted by soaring energy costs. Furthermore, a significant portion, 200 billion baht, is earmarked for accelerating Thailand’s transition to renewable energy sources.

Fiscal Concerns and Economic Justification

The opposition’s primary argument against the borrowing decree centers on Thailand’s current economic conditions and limited fiscal space. They contend that the economy is still expanding and that the country’s public debt, already nearing its self-imposed 70% of GDP cap, cannot sustain such massive new debt. Specifically, they question the rationale for financing the energy transition through additional borrowing. While the government, through Finance Minister Ekniti Nitithanprapas, argues that the borrowing is crucial to combat the economic crisis fueled by surging energy costs and to prevent stagflation, the opposition believes alternative measures, such as reducing excise taxes on fuel, would be more appropriate.

Government Reassurance and Economic Outlook

Despite opposition concerns, the government maintains that the borrowing will not compromise the nation’s overall fiscal discipline, as public debt will remain below the 70% voluntary cap. Finance Minister Ekniti Nitithanprapas stated that the new debt will be raised from the domestic market, which possesses ample liquidity. He emphasized that the global energy shocks have directly impacted household incomes and the cost of living, making state spending from new debt essential. The Bank of Thailand projects a slowdown in economic growth to 1.5% this year, from 2.4% in the previous year, highlighting the challenging economic climate and Thailand’s vulnerability due to its reliance on imported oil and natural gas.

Advertisement
Continue Reading

Business

Sumco Corporation 2026 Q1 – Results – Earnings Call Presentation (OTCMKTS:SUOPY) 2026-05-15

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Trending

Copyright © 2025